EBV-positive cutaneous B-cell lymphoproliferative disease after imatinib mesylate

Blood. 2003 Dec 1;102(12):4243. doi: 10.1182/blood-2003-07-2436.
No abstract available

Publication types

  • Case Reports
  • Letter

MeSH terms

  • Aged
  • B-Lymphocytes / pathology
  • Benzamides
  • Female
  • Herpesvirus 4, Human*
  • Humans
  • Imatinib Mesylate
  • Immunosuppression Therapy / adverse effects
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive / drug therapy
  • Lymphoproliferative Disorders / etiology*
  • Lymphoproliferative Disorders / pathology
  • Neoplasms, Second Primary / etiology*
  • Neoplasms, Second Primary / pathology
  • Piperazines / adverse effects*
  • Piperazines / therapeutic use
  • Pyrimidines / adverse effects*
  • Pyrimidines / therapeutic use
  • Skin Neoplasms / etiology*
  • Skin Neoplasms / pathology

Substances

  • Benzamides
  • Piperazines
  • Pyrimidines
  • Imatinib Mesylate